amplif
cultur
done
previous
viru
inocul
confluent
vero
cell
tissu
cultur
flask
multipl
infect
incub
humidifi
incub
hour
gentl
shake
everi
minut
subsequ
inoculum
replac
ml
viral
inocul
medium
dmem
fb
penicillinstreptomycin
mmoll
hepe
ph
cell
incub
humidifi
incub
hour
cell
show
cytopath
effect
cpe
supernat
collect
centrifug
remov
cellular
debri
minut
g
room
temperatur
viru
aliquot
store
titer
determin
plaqu
assay
whole
blood
unit
ml
collect
prepar
king
abdulaziz
univers
hospit
transfus
servic
jeddah
kingdom
saudi
arabia
voluntari
donor
briefli
blood
unit
centrifug
g
minut
separ
platelet
plt
plasma
plt
rich
plasma
centrifug
g
minut
plasma
separ
plasma
bag
kept
blood
unit
screen
routin
hcv
antibodi
antigen
hbsag
hbc
antibodi
hiv
antibodi
htlv
antibodi
syphili
well
hcv
hbv
hiv
nat
two
unit
plasma
ml
pool
experi
count
red
blood
cell
less
pool
plasma
total
four
pool
n
use
studi
pool
plasma
unit
inocul
approxim
ml
stock
dilut
plasma
unit
inactiv
intercept
process
set
plasma
intercept
illumin
accord
manufactur
instruct
residu
amotosalen
free
photoproduct
remov
intercept
compound
adsorpt
devic
accord
manufactur
instruct
sampl
collect
test
follow
fig
posit
control
sampl
viru
stock
neg
control
sampl
plasma
pool
inocul
pretreat
sampl
inocul
plasma
pool
inactiv
sampl
treat
pool
plasma
sampl
store
test
plaqu
revers
polymeras
chain
reaction
assay
detect
replic
sampl
dilut
dilut
dmem
fb
inocul
confluent
vero
cell
plate
incub
day
supernat
collect
dilut
dmem
fb
blindli
passag
two
time
passag
observ
cpe
collect
supernat
use
viral
rna
quantif
vero
cell
prepar
dmem
growth
medium
ml
seed
well
plate
incub
overnight
sampl
serial
dilut
inocul
dmem
start
dilut
appli
confluent
vero
cell
monolay
well
incub
hour
gentl
shake
everi
minut
hour
inoculum
remov
replac
overlay
medium
dmem
agaros
incub
day
incub
overlay
remov
cell
fix
paraformaldehyd
minut
room
temperatur
stain
crystal
violet
stain
plaqu
examin
count
calcul
titer
unit
pfu
ml
previous
experi
ml
plasma
test
plaqu
assay
detect
residu
infecti
viru
increas
dynam
rang
assay
neat
plasma
inocul
well
sampl
posit
neg
pretreat
inactiv
sampl
cell
supernat
rna
extract
previous
use
viral
rna
mini
kit
qiagen
accord
manufactur
instruct
perform
use
primer
probe
target
n
gene
previous
specif
follow
forward
primer
revers
primer
probe
use
perform
plate
fast
pcr
system
model
appli
biosystem
use
kit
quantitect
probe
qiagen
accord
manufactur
instruct
total
reaction
volum
rna
transcript
correspond
target
region
gener
use
cdna
synthesi
kit
superscript
rt
iii
invitrogen
plasmid
contain
n
gene
accord
manufactur
instruct
use
gener
standard
curv
estim
viral
rna
copi
number
sampl
previous
run
includ
posit
viral
templat
control
neg
control
sampl
test
duplic
mean
report
log
copiesml
sampl
report
neg
cycl
threshold
valu
higher
cycl
studi
approv
biomed
ethic
committe
unit
king
abdulaziz
univers
hospit
approv
evalu
potenti
ib
inactiv
pool
plasma
viru
spike
pool
plasma
unit
treat
amotosalen
uva
light
viral
titer
pretreat
sampl
rang
log
pfuml
mean
titer
log
pfuml
tabl
treatment
result
detect
viabl
virus
inactiv
sampl
plaqu
assay
mean
reduct
log
pfuml
viral
infect
titer
four
independ
experi
experi
fig
show
repres
result
plaqu
assay
therefor
larger
volum
inactiv
sampl
test
increas
sensit
dynam
rang
assay
shown
tabl
nonetheless
viabl
viru
detect
post
pathogen
inactiv
treatment
even
ml
plasma
test
viral
genom
titer
reduc
post
treatment
expect
tabl
togeth
data
show
amotosalenuva
light
pathogen
inactiv
technolog
inactiv
infecti
particl
spike
plasma
unit
next
analyz
presenc
potenti
low
level
replic
inactiv
plasma
unit
take
consider
genom
viral
titer
chang
treatment
tabl
end
vero
cell
inocul
plasma
sampl
unit
incub
day
follow
two
addit
passag
day
incub
cpe
observ
neg
control
inactiv
sampl
even
day
postinocul
passag
three
time
compar
posit
pretreat
sampl
complet
destroy
cell
day
data
shown
confirm
result
viral
genom
rna
titer
measur
supernat
collect
day
sampl
three
consecut
passag
shown
tabl
viral
genom
titer
posit
control
pretreat
sampl
rang
log
rna
copiesml
respect
three
passag
indic
presenc
replic
virus
sampl
hand
viral
rna
detect
supernat
collect
three
passag
neg
control
inactiv
sampl
confirm
complet
inactiv
infecti
plasma
current
known
pathogen
recogn
aabb
pathogen
concern
blood
transfus
howev
blood
donat
screen
small
number
pathogen
regular
basi
although
specif
pathogen
screen
test
blood
product
significantli
reduc
infect
transmiss
pathogen
hiv
hbv
hcv
still
report
mani
part
furthermor
emerg
andor
reemerg
pathogen
usual
zoonot
natur
pose
high
risk
blood
unpredict
natur
outbreak
errat
dynam
spread
repres
challeng
hurdl
prepared
plan
implement
safeti
measur
recent
exampl
emerg
zika
viru
flaviviru
transmiss
blood
outbreak
coronavirus
high
mortal
human
describ
china
southeast
middl
east
south
detect
viral
rna
blood
patient
infect
suggest
potenti
risk
transmiss
outbreak
south
korea
level
viral
load
rang
log
genom
copiesml
whole
blood
log
genom
copiesml
anoth
studi
report
log
rna
copiesml
serum
infect
correspond
approxim
infecti
titer
less
log
whole
blood
less
log
serum
accord
data
show
differ
genom
infecti
titer
tabl
use
ib
abl
show
mean
reduct
log
infecti
titer
rang
plasma
tabl
approxim
log
higher
minimum
reduct
titer
recommend
european
committe
blood
suggest
inactiv
capac
plasma
high
safeti
margin
contrast
infecti
titer
genom
titer
affect
slightli
pathogen
inactiv
treatment
tabl
amotosalenuva
process
effect
crosslink
nucleic
acid
break
strand
therefor
ensur
remain
amount
infecti
viru
particl
collect
supernat
passag
three
time
inactiv
day
absenc
cpe
even
day
incub
cultur
inocul
posttreat
sampl
suggest
infecti
remain
sampl
viral
genom
detect
supernat
cell
cultur
inocul
posttreat
sampl
even
multipl
passag
mostli
due
nonrepl
viral
genom
degrad
viral
rna
incub
period
contrast
pretreat
posit
control
sampl
show
high
level
viral
rna
incub
three
passag
demonstr
loss
infecti
viru
passag
success
inactiv
infecti
particl
ib
treatment
far
report
transmiss
via
blood
transfus
despit
detect
viral
rna
serum
infect
nonetheless
aabb
still
list
virus
pathogen
concern
blood
rna
detect
persist
patient
serum
day
evid
could
infect
replic
macrophag
dendrit
cell
cell
peripher
therefor
realli
clear
whether
presenc
rna
blood
serum
plasma
could
consequ
transmiss
risk
transfus
apart
recent
larg
blood
virom
studi
found
blood
studi
popul
healthi
blood
donor
contain
genet
materi
human
virus
includ
human
herpesvirus
ebv
cmv
human
papillomavirus
hbv
hcv
human
parvoviru
human
adenoviru
human
polyomavirus
merkel
cell
polyomaviru
trichodysplasia
spinulosa
polyomaviru
anelloviru
torqu
teno
viru
ttv
mini
viru
influenza
mani
virus
great
import
transfus
medicin
although
detect
blood
necessarili
impli
infect
sinc
genet
materi
detect
furthermor
nonhuman
viral
speci
also
detect
blood
mani
individu
attribut
contamin
commerci
reagent
nonetheless
identif
virus
gemycircularviru
suggest
due
contamin
phlebotomi
plasma
pool
process
therefor
target
test
blood
product
might
best
econom
logist
option
ensur
blood
safeti
abl
show
effici
inactiv
therapeut
human
plasma
unit
log
far
expect
viral
load
human
blood
serum
describ
recent
studi
investig
inactiv
plasma
use
riboflavin
uv
studi
show
reduct
least
least
log
viral
titer
pool
individu
donor
plasma
respect
howev
passag
experi
pathogen
reduct
conduct
complet
inactiv
infecti
particl
taken
grant
sever
previou
studi
also
prove
effici
ib
inactiv
larg
number
pathogen
virus
bacteria
parasit
studi
describ
add
list
pathogen
inactiv
ib
taken
togeth
previous
publish
work
data
show
ib
could
repres
econom
logist
effici
protect
solut
reduc
risk
associ
circul
arabian
peninsula
potenti
transmiss
also
known
unknown
pathogen
commerci
avail
screen
assay
author
disclos
conflict
interest
